The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.
Journal
Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
12
12
2022
accepted:
23
01
2023
revised:
18
01
2023
medline:
5
4
2023
pubmed:
5
2
2023
entrez:
4
2
2023
Statut:
ppublish
Résumé
Mutant TP53 proteins are thought to drive the development and sustained expansion of cancers at least in part through the loss of the wild-type (wt) TP53 tumour suppressive functions. Therefore, compounds that can restore wt TP53 functions in mutant TP53 proteins are expected to inhibit the expansion of tumours expressing mutant TP53. APR-246 has been reported to exert such effects in malignant cells and is currently undergoing clinical trials in several cancer types. However, there is evidence that APR-246 may also kill malignant cells that do not express mutant TP53. To support the clinical development of APR-246 it is important to understand its mechanism(s) of action. By establishing isogenic background tumour cell lines with different TP53/TRP53 states, we found that APR-246 can kill malignant cells irrespective of their TP53/TRP53 status. Accordingly, RNAseq analysis revealed that treatment with APR-246 induces expression of the same gene set in Eμ-Myc mouse lymphoma cells of all four possible TRP53 states, wt, wt alongside mutant, knockout and knockout alongside mutant. We found that depending on the type of cancer cell and the concentration of APR-246 used, this compound can kill malignant cells through induction of various programmed cell death pathways, including apoptosis, necroptosis and ferroptosis. The sensitivity of non-transformed cells to APR-246 also depended on the cell type. These findings reveal that the clinical testing of APR-246 should not be limited to cancers expressing mutant TP53 but expanded to cancers that express wt TP53 or are TP53-deficient.
Identifiants
pubmed: 36739334
doi: 10.1038/s41418-023-01122-3
pii: 10.1038/s41418-023-01122-3
pmc: PMC10070280
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1033-1046Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Cell Rep. 2015 Mar 3;10(8):1422-32
pubmed: 25732831
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Commun. 2021 Dec 3;12(1):7057
pubmed: 34862374
Cancers (Basel). 2017 Dec 16;9(12):
pubmed: 29258181
Bioinformatics. 2017 Jul 01;33(13):2050-2052
pubmed: 28203714
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3964-9
pubmed: 19225112
Nature. 2006 Jan 5;439(7072):84-8
pubmed: 16397499
Hum Mutat. 2003 Mar;21(3):313-20
pubmed: 12619118
Nature. 2007 Feb 8;445(7128):656-60
pubmed: 17251933
Sci Rep. 2018 Aug 23;8(1):12671
pubmed: 30140002
Nature. 1992 Mar 19;356(6366):215-21
pubmed: 1552940
Redox Biol. 2020 Jan;28:101328
pubmed: 31574461
Oncogene. 2010 Mar 4;29(9):1329-38
pubmed: 19946333
Br J Cancer. 2021 Nov;125(11):1523-1532
pubmed: 34599296
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nature. 2007 Feb 8;445(7128):661-5
pubmed: 17251932
Mol Cancer Ther. 2021 Oct;20(10):1858-1867
pubmed: 34315763
Nat Rev Cancer. 2009 Oct;9(10):749-58
pubmed: 19776744
Nat Med. 2002 Mar;8(3):282-8
pubmed: 11875500
Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63
pubmed: 24355989
Cell Death Dis. 2015 Jun 18;6:e1794
pubmed: 26086967
Blood. 2021 May 20;137(20):2721-2735
pubmed: 33824975
Nat Rev Mol Cell Biol. 2007 Apr;8(4):275-83
pubmed: 17380161
Immunity. 2013 Sep 19;39(3):443-53
pubmed: 24012422
Oncotarget. 2015 Nov 3;6(34):36689-99
pubmed: 26452133
Science. 2004 Feb 6;303(5659):844-8
pubmed: 14704432
Genes Dev. 1999 Oct 15;13(20):2658-69
pubmed: 10541552
Blood. 2010 Dec 9;116(24):5256-67
pubmed: 20829369
Nature. 1985 Dec 12-18;318(6046):533-8
pubmed: 3906410
Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1480-9
pubmed: 23542378
Oncogene. 1995 Dec 7;11(11):2411-8
pubmed: 8570193
J Clin Oncol. 2021 May 10;39(14):1584-1594
pubmed: 33449813
Nucleic Acids Res. 2013 May 1;41(10):e108
pubmed: 23558742
Front Pharmacol. 2018 Nov 22;9:1371
pubmed: 30524291
J Biol Chem. 2016 May 13;291(20):10847-57
pubmed: 26994140
Nat Rev Mol Cell Biol. 2020 Nov;21(11):678-695
pubmed: 32873928
Blood. 2014 Sep 4;124(10):1626-36
pubmed: 25006124
Bio Protoc. 2022 Apr 20;12(8):e4394
pubmed: 35800090
Ann Appl Stat. 2016 Jun;10(2):946-963
pubmed: 28367255
Development. 2017 Mar 15;144(6):1065-1071
pubmed: 27993977
Oncogene. 2019 Jun;38(24):4729-4738
pubmed: 30765862
Cell. 2017 Sep 7;170(6):1062-1078
pubmed: 28886379
Cell Death Dis. 2013 Oct 24;4:e881
pubmed: 24157875
Nat Commun. 2018 Jun 21;9(1):2422
pubmed: 29930286
Genome Biol. 2010;11(3):R25
pubmed: 20196867
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Cell Death Differ. 2017 Mar;24(3):481-491
pubmed: 28106882
Front Immunol. 2019 Jan 22;9:3134
pubmed: 30723477
Nat Med. 1997 Jun;3(6):632-8
pubmed: 9176489
Genes Dev. 2012 Jun 15;26(12):1268-86
pubmed: 22713868
Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):15078-15083
pubmed: 27965388
Nat Rev Cancer. 2022 Jan;22(1):45-64
pubmed: 34663943
Cell Cycle. 2011 Jan 15;10(2):301-7
pubmed: 21239882
FEBS Lett. 2014 Aug 19;588(16):2622-7
pubmed: 24768524
Nature. 2021 Mar;591(7848):131-136
pubmed: 33472215
Science. 2003 Nov 7;302(5647):1036-8
pubmed: 14500851
Nat Rev Mol Cell Biol. 2010 Oct;11(10):700-14
pubmed: 20823910
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970
Leuk Lymphoma. 2017 Mar;58(3):676-688
pubmed: 27338091
Haematologica. 2022 Feb 01;107(2):403-416
pubmed: 33406814
Front Immunol. 2016 Mar 01;7:75
pubmed: 26973652